title: Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.
abstract: We report a 76-year-old woman with extra nodal NK/T-cell lymphoma nasal type (ENKL). She had large tumors on her left leg with inguinal lymphadenopathy and gastric tumors. The tumor cells showed angiocentric growth with necrosis. Immunohistologically, the tumor cells from the skin lesion expressed CD2, cytoplasmic CD3, CD56, and T-cell intracellular antigen-1 (TIA-1), but not surface CD3, CD19, and TdT. The gastric tumor cell, also expressed cytoplasmic CD3, CD45RO and CD56. She was diagnosed as having ENKL (stage IV of Ann Arbor). The tumors responded remarkably well to radiation therapy followed by multi-drug resistance independent DeVIC (carboplatin, etoposide, ifosfamide, and dexamethasone) combination therapy. After two series of this therapy, no tumors were detected in clinical, histopathological, endoscope and computerized tomogram (CT) examinations. However, she suddenly died of brain stem metastasis three months later. Although there may be a limitation of effects on metastasis of tumors in the central nervous system, radiation and DeVIC combination therapy is a potent therapeutic method for ENKL.
authors.affiliation: Department of Dermatology, Mie University, Faculty of Medicine, Tsu, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Nomura
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Isoda
authors.forename: Keiichi
authors.initials: K
authors.lastname: Yamanaka
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Arata
authors.initials: A
authors.lastname: Hakamada
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Mizutani
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D016190:Carboplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D018450:Disease Progression; D005047:Etoposide / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000473:pathology* / Q000628:therapy*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012878:Skin Neoplasms / Q000473:pathology* / Q000628:therapy*
chemical_list: D005047:Etoposide; D003907:Dexamethasone; D016190:Carboplatin; D007069:Ifosfamide